Get the Stockscreener App
141.70
4.73%
-7.04
After Hours:
141.70
Neurocrine Biosciences Inc stock is traded at $141.70, with a volume of 1.74M.
It is down -4.73% in the last 24 hours and down -1.30% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$148.74
Open:
$150.47
24h Volume:
1.74M
Relative Volume:
1.77
Market Cap:
$14.13B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
48.03
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-8.95%
1M Performance:
-1.30%
6M Performance:
+13.47%
1Y Performance:
+3.67%
1-Day Range:
$141.61
$150.47
1-Week Range:
$141.61
$156.46
52-Week Range:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
141.70 | 14.83B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
122.25 | 54.31B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.47 | 45.90B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.86B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.06 | 34.53B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
510.94 | 21.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat
Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets
Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com UK
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada
Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter
Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com UK
Neurocrine Bio. stock holds steady as BMO reiterates $147 price target - Investing.com UK
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire
What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in
Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st
Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX is Braidwell LP's 3rd Largest Position - MarketBeat
Ieq Capital LLC Buys 35,956 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mizuho raises Neurocrine Bio. stock price target to $175 on Crenessity outlook - Investing.com India
Stifel Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Stifel Nicolaus Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Neurocrine Biosciences chief legal officer Lippoldt sells $698k in stock - Investing.com Canada
Neurocrine Bio. stock rating reiterated at Buy by TD Cowen - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $698,628.40 in Stock - MarketBeat
Neurocrine Biosciences Insider Sold Shares Worth $698,615, According to a Recent SEC Filing - marketscreener.com
Diadema Partners LP Has $11.82 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Axa S.A. - MarketBeat
Amundi Has $28.36 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences to Host R&D Day on December 16 - Sahm
Arrowstreet Capital Limited Partnership Acquires 58,562 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
RBC Capital Maintains Neurocrine Biosciences (NBIX) Outperform Recommendation - Nasdaq
RBC Capital Initiates Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $180 - 富途牛牛
Neurocrine Biosciences (NASDAQ:NBIX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 By Investing.com - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $180.00 - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating - marketscreener.com
Hood River Capital Management LLC Sells 79,626 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Bio. stock price target raised to $180 from $160 at RBC Capital - Investing.com
First Trust Advisors LP Lowers Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
1832 Asset Management L.P. Purchases New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) valuation update after NBI-1070770 Phase 2 trial failure reshapes pipeline expectations - Sahm
Earnings Recap: How Neurocrine Biosciences Inc stock performs in weak economyWeekly Trade Report & High Accuracy Trade Alerts - moha.gov.vn
TD Cowen Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Growth Value: How MSPRO stock compares to industry benchmarksQuarterly Performance Summary & AI Powered Market Entry Strategies - BỘ NỘI VỤ
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc. - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level - Investor's Business Daily
Saturn V Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):